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Abstract: Clinical outcome of hyperthermia depends on the achieved target temperature, therefore
target conformal heating is essential. Currently, invasive temperature probe measurements are the
gold standard for temperature monitoring, however, they only provide limited sparse data. In contrast,
magnetic resonance thermometry (MRT) provides unique capabilities to non-invasively measure
the 3D-temperature. This study investigates MRT accuracy for MR-hyperthermia hybrid systems
located at five European institutions while heating a centric or eccentric target in anthropomorphic
phantoms with pelvic and spine structures. Scatter plots, root mean square error (RMSE) and
Bland–Altman analysis were used to quantify accuracy of MRT compared to high resistance thermistor
probe measurements. For all institutions, a linear relation between MRT and thermistor probes
measurements was found with R2 (mean ± standard deviation) of 0.97 ± 0.03 and 0.97 ± 0.02,
respectively for centric and eccentric heating targets. The RMSE was found to be 0.52 ± 0.31 ◦C and
0.30 ± 0.20 ◦C, respectively. The Bland-Altman evaluation showed a mean difference of 0.46 ± 0.20 ◦C
and 0.13 ± 0.08 ◦C, respectively. This first multi-institutional evaluation of MR-hyperthermia hybrid
systems indicates comparable device performance and good agreement between MRT and thermistor
probes measurements. This forms the basis to standardize treatments in multi-institution studies of
MR-guided hyperthermia and to elucidate thermal dose-effect relations.
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1. Introduction
Hyperthermia is an emerging treatment modality for malignant cancer which is performed in
conjunction with chemotherapy and/or radiotherapy [1,2]. The aim of hyperthermia systems is to ensure
tumour selective heating, ideally within the narrow range of 40–44 ◦C, while restricting the heating of
surrounding healthy tissues to prevent toxicity [3]. Clinical trials have reported thermal dose-effect
relations [4–9] which strongly supports the need for measuring 3D-temperature combined with
precise control of the generated heating pattern to apply the maximum achievable thermal dose. The
implementation of quality assurance (QA) measures is essential to assure reliable system performance
and to maximize the delivery of a specific thermal dose to achieve effective therapy. We previously
reported that magnetic resonance thermometry (MRT) measurements using phantoms provide 3D-QA
capabilities [10] to evaluate the performance of MR-compatible hyperthermia applicators. Earlier, an
elliptical cylindrical phantom containing bone structures was extensively used in the QA evaluation of
the first BSD-2000-3D MR-compatible system (Pyrexar Medical Corp., Salt Lake City, UT, USA) [11].
In this work we use a human shape representative phantom including a realistic pelvic bone and
spine structures. To our knowledge, such a realistic anthropomorphic phantom has not been utilized
before to evaluate the accuracy of MRT against gold standard temperature probes used in clinical
treatments. In addition, this is the first comprehensive analysis of MRT accuracy across multiple
clinical MR-compatible systems installed in different hyperthermia institutions.
Current clinical QA guidelines for the application of hyperthermia [12–14] focus on non-MR
compatible heating systems, which have a limited number (usually up to eight) of intraluminal
(minimally invasive) and invasive/interstitial thermometry probes [15,16]. Such thermometry using
high resistance thermistor probes, fibre-optic temperature probes or thermocouples is considered the
gold standard to control the clinical delivery of the hyperthermia treatment. The drawback of using
probes is that they provide only temperature data with a limited spatial and temporal resolution at
certain locations or along the implanted catheter, by moving the probe inside. In addition, interstitial
thermometry is associated with potential risks such as haemorrhages, infections, acute side effects, and
furthermore, it is considered relatively time-consuming. Therefore, it has low acceptance by patients
and physicians [17,18].
MRT offers the unprecedented advantage of non-invasively monitoring temperature changes
in the treated volume and in the surrounding regions. Clinical MR-guided hyperthermia was first
introduced in the late 1990s and early 2000s [19–21]. Currently, the combination of an MR-compatible
applicator within an MR-system, so-called MR-hyperthermia hybrid system is considered the most
advanced hyperthermia technology for treatment of deep pelvic cancers and extremities providing
3D non-invasive thermometry. While installation of MR-hyperthermia hybrid systems is still limited
to a few institutions worldwide, the number of systems within the hyperthermia community has
increased during the last decade. The growing interest in monitoring hyperthermia treatments with
full 3D-dosimetry is leading to more institutions actively developing MR-hyperthermia hybrid systems
for other tumour locations as in head and neck [22], and brain [23] and the involvement of a broader
scope of MR-vendors. Currently, the only commercial MR-compatible deep hyperthermia applicators
in clinical use are the BSD-2000-3D with the Sigma-Eye and Universal Applicator (Pyrexar Medical
Corp., Salt Lake City, UT, USA) for the treatment of pelvic and extremity tumours in adults. These
applicators have been integrated into MR-systems of three of the major MR-suppliers (GE, Philips,
and Siemens). Since QA procedures for these hybrid systems are minimal, there is a strong need to
investigate if these devices have comparable performance in heating pattern quality and in temperature
monitoring, which are the prerequisites for multi-institutional studies.
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Gellermann et al. evaluated the feasibility of various MRT methods for deep hyperthermia in
a Siemens MR-scanner and using the first MR-compatible Sigma-Eye applicator in a homogeneous
phantom [24]. They concluded that the evaluated MRT methods achieved a temperature resolution
with respect to thermistor probe measurements in the range of ±0.5 to ±1 ◦C. Additionally, the same
group evaluated the accuracy of the proton-resonance frequency shift (PRFS) method, which is the
most widely used MRT method, versus thermistor probe measurements for their deep hyperthermia
system using a heterogeneous phantom [11]. They found that the PRFS method could reproduce probe
measurements with an accuracy of ±0.4 to ±0.5 ◦C. Following, Tarasek et al. evaluated the accuracy
of the PRFS method and thermistor probes for a head and neck applicator operating within a GE
system and they also obtained an overall temperature accuracy within <0.5 ◦C [25]. Furthermore,
Gellermann et al. studied the potential of MRT in patients with recurrent rectal carcinoma with
presacral location [26]. They concluded that MRT was feasible for regional hyperthermia and they
found a correlation between MRT and tumour related thermistor probe readings of R2 = 0.67. In
a follow-up study, they evaluated MRT for monitoring hyperthermia treatments in patients with
soft tissue sarcomas of the lower extremities and pelvis [27]. They found an excellent correlation
between MRT and thermistor probe readings (R2 = 0.96). In a more recent study, Craciunescu et al. [28]
evaluated the accuracy of MRT vs. fibre optic probe measurements for high-grade extremity soft tissue
sarcomas using a GE Signa Excite scanner and an in-house developed phased array hyperthermia
applicator. They obtained excellent agreement between MRT and invasive thermometry probes with a
mean difference between both techniques of 0.91 ◦C.
The MR-compatible deep hyperthermia applicators installed at the five evaluated hyperthermia
institutions operate within MR-systems of three major MR-vendors at a field strength of 1.5 T (see
Figure 1A). Hence, the hybrid systems may experience differences in magnet configuration, quality of
gradients, protocol parameters of the PRFS-method, the image quality, etc., all potentially influencing
the accuracy of the MRT. To the best of our knowledge, there is no study comparing and evaluating
the performance of the different hyperthermia applicators operating in the multi-vendor MR-systems
with respect to MRT accuracy. Therefore, to improve comparison of clinical results from different
institutions, we systematically and quantitatively assessed the temperature accuracy of the MRT against
the thermistor probes, as gold standard, across the five hybrid-systems installed at the University
Hospitals of Düsseldorf (Siemens, Sigma Eye), Erlangen (Siemens, Sigma Eye), Munich (Philips,
Universal Applicator) and Tübingen (Siemens, Sigma Eye), in Germany and the Erasmus MC Cancer
Institute (GE, Sigma Eye) in Rotterdam, The Netherlands. The long-term aim of this work is to
contribute to the development of comprehensive QA-guidelines for existing and new MR-guided
hyperthermia systems as a solid foundation for multi-institution clinical trials and to elucidate thermal
dose-effect relations.
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performed MR scans (E).
2. Methods and Materials
2.1. Phantom Development
Two similar, but not identical, anthropomorphic phantoms with representative shape and
dimensions of an adult male were specifically developed to evaluate the MR-heating performance
of the hybrid systems at the different institutions. A transparent male mannequin of wall thickness
4 mm (BP01037, Shophouse, Ede, The Netherlands) with a detailed anatomical body shape was used
as the phantom shell. Artificial plastic pelvic, spine bones and discs of a full-body anatomical skeleton
(180 cm) (VM101, Vosmedisch, Amsterdam, The Netherlands) were positioned inside the shell (see
Figure 1B,C). While phantoms containing bone structures have been previously presented in literature
for deep hyperthermia evaluations [11], this work reports for the first time the use of human shape
representative phantoms. Holes with diameter of 2.5 mm spaced ~15 mm apart were drilled on the
phantom shell in the perineum area. Closed-tip catheters with 350 mm length, 1.10 mm ID and 2 mm
OD (Somatex, Medical Technologies GmbH, Berlin, Germany), i.e., the same catheters used clinically in
deep hyperthermia treatments at the Erasmus MC Cancer Institute, were inserted through the drilled
holes and positioned inside and around the bone structure. Dielectric properties of the phantom shell
and artificial bones were relative permittivity of 2.8 and effective conductivity of 0 S/m at 100 MHz. The
phantom shell was filled with a mixture of sodium benzoate, agar and deionized water (10 g sodium
benzoate and 20 g agar per 1000 g demineralized water). Dielectric properties of the phantom were
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measured with a Dielectric Assessment Kit (DAK, Speag, Zurich, Switzerland) at room temperature
of 21 ◦C. The measured values were relative permittivity of 78.6 ± 0.03 and effective conductivity of
0.41 ± 0.0002 S/m at 100 MHz.
The two phantoms were produced following the same methodology. One of the phantoms was
always used to evaluate focus steering for centric heating target while the other one was always used
to evaluate focus steering for eccentric heating target. Only one measurement can be performed per
phantom per day due to the phantom’s need to cool down and stabilize its temperature. Therefore,
two similar phantoms were produced to perform centric and eccentric measurements in one day. The
centre of the phantom was defined and labelled on the phantom surface by a graphite cylinder of
12mm length and 0.8mm outer diameter that is visible in CT. Four high resistance thermistor probes
(Pyrexar Medical Corp., Salt Lake City, UT, USA) were inserted in the catheters and the alignment of
the temperature probes with the centre of the phantom was determined by CT-guidance. The labelled
center of the phantom was then positioned at the centre of the Pyrexar BSD2000-3D-MR Sigma Eye or
Pyrexar BSD2000-3D-MR Universal Applicator (Figure 1D). In order to reduce the associated spatial
and temporal uncertainty, the probes were kept fixed at the central position and no mapping of the
probes was performed.
2.2. QA Measurements
Phantoms were acclimatised at the MR-room temperature starting the day before performing
the MR-measurements in order to exclude any residual temperature gradients. The same set of
measurements was performed at each of the five European hyperthermia institutions with a hybrid
BSD2000-3D MR-system. All systems are maintained following the service contract from the supplier
(Dr. Sennewald Medizintechnik GmbH, Munich, Germany). Focus steering was applied directly in
these ‘clinical’ ready to use systems. Hence, the measurements are considered to provide real time
and realistic reflection of the daily performance of the system. With the phantoms positioned in the
same way, steering accuracy of the applicator focus was assessed for two steering conditions, aiming
to have a centric focus at the (0, 0, 0) cm location and a focus at an eccentric location of (3, 0, 0) cm.
High resistance thermistor probes and MRT measurements were performed applying equal power
to each of the twelve channels of the applicator with a total clinically relevant power of 600W for a
duration of approximately 12 min.
The PRFS method was used to monitor the MRT during the measurements [10,29–32]. Standard
gradient-echo (GRE) sequences with two echo times were used. A high-resolution scan was used to
verify the correct positioning of the phantom, detect air pockets inside the water bolus and delineate
the fat-like references attached inside the applicator which are used to compensate for B0 drift [10]
during the measurements. Two MRT scans were performed as a baseline without heating. Afterwards,
eight consecutive MRT scans were acquired with RF-power to the hyperthermia applicator switched
on, consecutively followed by a ninth scan with RF-power switched off, as shown in Figure 1E. All
scans were performed with the following parameters: 25 axial slices, slice thickness of 10 mm, no
separation between slices, and a field of view (FoV) of 50 × 50 cm. Table 1 shows the main parameters
of the scans at the five institutions as used in their clinical routine and the reported measurements here.
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Table 1. MR sequences parameters as used during the clinical routine and during the performed
experiments at the five institutions, for High Resolution scans and Magnetic Resonance Thermometry
(MRT) scans.
Institution Scan Type TR (ms) TE1 (ms) TE2 (ms) FA (deg) AcquisitionMatrix
Reconstruction
Matrix
Scan Time
(sec)
1
High
Resolution 120 4.8 9.60 70 256/256 256/256 136
MRT 620 4.8 19.1 40 128/128 256/256 83
2
4
5
High
Resolution 120 4.76 9.53 70 256/256 256/256 124
MRT 600 4.76 19.10 50 128/128 128/128 78
3
High
Resolution 120 4.60 9.21 70 252/250 256/256 151
MRT 600 4.60 18.42 50 128/128 256/256 79
2.3. Data Analysis
MR-data was processed with the MRT package Sigma Vision Advance (Dr. Sennewald
Medizintechnik GmbH, Munich, Germany) to obtain the MR-3D thermal maps per scan. The MR-3D
thermal maps were then imported into Matlab (version R2016b, MathWorks, Natick, MA, USA)
for quantitative analysis. In the first step, the catheter locations were identified in the magnitude
MR-images. To evaluate the MRT, a region of interest (ROI) of 15.625 mm-side lengths centred
in each catheter location was selected in the central axial slice. This ROI dimension corresponds
with the minimum square containing 4 × 4 pixels for Institutions 2, 4, and 5 (reconstruction matrix:
128 × 128 pixels, pixel size 3.906 mm). The centre 2 × 2 pixels of the ROI containing the catheters
were neglected from the calculation to prevent the inclusion of pixels containing signal void from the
plastic catheters. For Institutions 1 and 3 (reconstruction matrix: 256 × 256 pixels, pixel side length of
1.953 mm), to obtain the same ROIs of 15.625 mm-side lengths, 8 × 8 pixels were evaluated, from which
the centric 4 × 4 pixels containing the catheters was neglected. The mean and standard deviation values
were obtained from the ROI of each time-specific thermal map. Thermistor probes measurements were
taken every 10 seconds over the full heating and cooling period.
A qualitative comparison of the temperature increase was performed by including the temperature
readings from the four thermistor probes and their related MRT as evaluated in the four ROI (mean
and standard deviation) for each specific time-scan. For quantitative comparison, scatter plots of
both temperature measurement methods with determination of regression lines and R2 were used.
Regression analysis quantifies the linear relationship between the two measurement methods however
it does not quantify accuracy [33,34]. Accuracy between the measurement methods was quantified
by additionally applying the root mean squared error (RMSE) analysis [35]. To further visualize the
difference between the two-measurement methods Bland-Altman analysis was used [36]. Within the
Bland-Altman analysis, the mean (m) and standard deviation (σ) of the differences between both
measurement methods were computed. The values of m ± 2σ were also determined, as most of the
differences (95% for the assumed Gaussian distribution) are expected to fall between these two limits.
This procedure was previously used in Dadakova et al. [37]. The regression analysis, RMSE and
Bland-Altman evaluations were carried out using the R statistical package (version 3.2.4, 2016, The R
Foundation for Statistical Computing, Vienna, Austria).
3. Results
3.1. Influence of Cable Length
Cables of different lengths are used to connect the hyperthermia amplifier and the 12 dipole
antenna pairs of each system, and consequently, the power lost on the cables differs among systems.
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Power losses on the cables at the five institutions are: 30.3%, 25.3%, 25.8%, 23.3%, and 26.5%, respectively
for Institution 1 to 5.
3.2. MRT vs. Thermistor Probe Measurements Evaluation
3.2.1. Centric Heating Target
The temporal evolution of temperature increase determined by thermistor probes and by computed
MRT for a centric heating target is shown in Figure 2. The four evaluated locations are indicated
in Figure 2 top left. Table 2 shows the temperature increases for all 4 thermistor probes and the
corresponding average of MRT in the evaluated ROIs after 600 sec of heating. Minor differences in
system responses can be seen at the 5 institutions, though the mean temperatures (thermistor probe
and MRT) all agree within 1 ◦C. Institution 1 showed that the more centric locations 3 and 4 featured
more temperature increase compared to the off-centric locations 1 and 2, which is in accordance with
the intended centric target. The average temperature increases (±SD) at 600 sec were 5.0 ± 0.3 ◦C and
4.0 ± 0.3 ◦C for thermistor probes and MRT, respectively. Institution 2 showed higher temperature
increase at location 1 compared with the other evaluated locations. The average temperature increase at
600 sec was 5.7 ± 0.7 ◦C for the thermistor probes and 5.4 ± 0.5 ◦C for the MRT. Considering Institution
3, the mean temperature increase was 4.3◦C ± 0.1◦C for the thermistor probes and 3.5 ± 0.2 ◦C for
the MRT. Institution 4 featured the lowest power loss in the cables between amplifier and antenna
elements, however temperature increase at this institution was not the highest compared to other
institutions. The mean temperature increase at 600 sec was 4.0 ± 0.1 ◦C for the thermistor probes and
3.5 ± 0.3 ◦C for the MRT. The fifth institution featured an average value of the temperature increase at
600 sec of 3.7 ± 0.4 ◦C and 2.7 ± 0.4 ◦C for the thermistor probes and MRT, respectively. Scatter plots in
Figure 3 show the MRT in comparison to thermistor probes measurements for centric heating target
for the four-probe locations. For each institution a highly linear relation was determined. The mean
R2 across the five institutions was found to be 0.97 ± 0.03 (0.93–1.0). As a qualitative note, results
in Figure 3 enlighten that the computed MRT slightly underestimates the temperature measured by
thermistor probes. The Bland–Altman plots for thermistor probes and MRT for centric heating target
are shown in Figure 4. The overall mean (m) temperature difference (thermistor reading is higher than
MRT) and standard deviation (σ) between both measurement methods are m = 0.46 ± 0.20 (0.15–0.65)
◦C and σ = −0.36 ± 0.06, respectively. The m − 2σ was found to be (−0.27 ± 0.16) ◦C and m + 2σ =
(1.18 ± 0.28) ◦C. The RMSE across the five institutions were found to be 0.52 ± 0.31 (0–0.77) ◦C.
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Table 2. Temperature increase at 600 sec for centric heating target measured with thermistor probes
and computed Magnetic Resonance Thermometry (MRT).
Institution Temperature
Measurement
Mean Temperature Increase [∆T (◦C)] at Locations 1 to 4 Mean Temperature
Increase± SD (◦C)∆T Location 1 ∆T Location 2 ∆T Location 3 ∆T Location 4
1
Thermistor
probe 4.7 4.6 5.2 5.3 5.0 ± 0.3
MRT 3.8 3.5 4.3 4.3 4.0 ± 0.3
2
Thermistor
probe 6.8 4.7 5.6 5.6 5.7 ± 0.7
MRT 6.2 4.9 5.3 5.1 5.4 ± 0.5
3
Thermistor
probe 4.4 4.2 4.4 4.3 4.3 ± 0.1
MRT 3.6 3.2 3.7 3.5 3.5 ± 0.2
4
Thermistor
probe 4.1 4.1 3.9 4.0 4.0 ± 0.1
MRT 3.2 3.9 3.5 3.3 3.5 ± 0.3
5
Thermistor
probe 3.2 3.4 4.0 4.2 3.7 ± 0.4
MRT 2.3 2.4 3.0 3.3 2.7 ± 0.4
3.2.2. Eccentric Heating Target
Figure 5 illustrates the temperature increase of the thermistor probes as well as the computed
MRT, for eccentric heating target. Table 3 shows the temperature increase for each thermistor probe and
MRT at 600 sec of heating. For Institution 1, the mean temperature increase at 600 sec was 4.0 ± 1.2◦C
and 3.5 ± 1.3◦C for the thermistor probes and MRT, respectively. Higher temperature increase could be
seen in Institution 2 with an average temperature increase at 600 sec of 5.6 ± 1.1◦C for the thermistor
probes and 5.3 ± 1.3◦C for the MRT. The acquired data of Institution 3 showed a mean temperature
increase at 600 sec of 3.5 ± 0.8◦C from the thermistor probes and 3.3 ± 0.9◦C calculated from the MRT.
Institution 4 featured a temperature increase at 600 sec of 3.0 ± 0.3◦C for the thermistor probes and
3.0 ± 0.4◦C for the MRT. Finally, the results of the quantitative evaluation of Institution 5 indicated
the lowest average heating when compared to the other systems and preferential heating towards
patient’s left side. The averaged values for the temperature increase at 600 sec were 2.5 ± 1.2◦C and
2.3 ± 1.6◦C for the thermistor probes and MRT, respectively. The scatter plots with regression lines
(Figure 6) for eccentric heating target present a R2 value for all institutions of 0.97 ± 0.02 (0.94–1.0),
additionally, good agreement between regression line and identity line was found. The Bland–Altman
analysis for eccentric heating target (Figure 7) showed a mean (m) and standard deviation (σ) between
both measurements equal to m = 0.13 ± 0.08 (0.03–0.25) ◦C, and σ = 0.32 ± 0.09, and consequently
m − 2σ= (−0.52 ± 0.19) ◦C and m + 2σ= (0.81 ± 0.26) ◦C. The RMSE for all institutions was found to be
0.30 ± 0.20 (0–0.48) ◦C.
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Table 3. Temperature increases at 600 sec for eccentric heating target measured with thermistor probes
and computed Magnetic Resonance Thermometry (MRT).
Institution Temp.
Measurem.
Mean Temperature Increase
[∆T (◦C)] at Locations 1 to 4 Mean Temp.
Increase ± SD (◦C)
d(∆T Location 4- ∆T
Location 1) (◦C)
∆T
Location 1
∆T
Location 2
∆T
Location 3
∆T
Location 4
1
Thermistor
probe 2.6 3.2 4.3 5.9 4.0 ± 1.2 3.3
MRT 2.0 2.7 4.1 5.3 3.5 ± 1.3 3.3
2
Thermistor
probe 4.5 4.7 6.1 7.2 5.6 ± 1.1 2.7
MRT 3.8 4.3 6.0 7.0 5.3 ± 1.3 3.2
3
Thermistor
probe 2.5 3.0 3.7 4.6 3.5 ± 0.8 2.1
MRT 2.3 2.5 3.9 4.4 3.3 ± 0.9 2.0
4
Thermistor
probe 2.7 2.9 3.0 3.6 3.0 ± 0.3 0.9
MRT 2.6 2.8 3.2 3.7 3.0 ± 0.4 1.1
5
Thermistor
probe 1.3 1.7 2.8 4.3 2.5 ± 1.2 3.0
MRT 0.6 0.9 3.2 4.6 2.3 ± 1.6 3.9
4. Discussion
In this work, the performance of clinically used MR-guided deep hyperthermia applicators was
for the first time systematically compared and evaluated in five European institutions in Germany and
The Netherlands. For such comparison, a new dedicated phantom type with a realistic human-shape
including implemented artificial bone structures was developed. Two phantoms of this type were
transported to each of the five institutions where the same experimental procedure was applied for the
QA measurements performed by the same principal investigator. Measurements were performed to
evaluate the MRT vs. thermistor probes accuracy for centric and eccentric focus steering.
The system efficiency in terms of power loss in the cables connecting the amplifier and antennas
was determined and it is found to be 26.2 ± 2.3% across the five systems. The differences are explained
by structural design conditions of the treatment rooms leading to variation in the cable lengths.
However, this difference in power loss is not directly reflected in the temperature increase values. For
example, Institution 1, which presents the highest power loss but not the lowest temperature increase.
This indicates that other interrelated factors can be present such as differences in antenna matching,
the coupling between antennas or phase induced errors at the antennas feed point [38,39].
The temporal evolution of thermistor probes and MRT change during the QA measurements
(Figures 2 and 5) of the five hyperthermia systems exhibit comparable heating performance but different
maximum temperatures change for both heating targets. For centric heating target, the overall mean
thermistor probe and MRT increase at 600 sec was 4.5 ± 0.7 ◦C and 3.8 ± 0.9 ◦C for the five institutions,
respectively (Figure 2 and Table 2). This indicates that the temperature readings of all systems perform
equally accurate. For eccentric target and evaluating Institutions 1, 2, 3, and 5, differences between the
temperature increase at location 4 and location 1 (Figure 5 and Table 3, note that location 4 is near the
eccentric focus whereas location 1 is farthest from the focus) were 2.8 ± 0.4 ◦C and 3.1 ± 0.7 ◦C, for
thermistor probes measurements and MRT, respectively. This indicates good overall steering of heating
target. If Institution 4 was also considered, differences between the temperature increase at location 4
and location 1 reduced their mean value and increased the SD, to 2.4 ± 0.8 ◦C for thermistor probes
and 2.7 ± 1.0 ◦C for MRT. This indicates a different steering capability of the system at Institution 4
compared with the rest of the systems. However, the linear regression and Bland-Altman evaluation
of Institution 4 indicates a very good correlation and agreement between thermistor probes and
MRT measurements.
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The excellent correlation between MRT and invasive thermistor probes was quantified by
the linear regression analysis with R2 of 0.97 ± 0.03 (0.93–1.0) for centric heating target and R2 of
0.97 ± 0.02 (0.94–1.0) for eccentric heating target (Figures 3 and 6). Closer agreement between regression
line and identity line was found for the measurements of eccentric heating as compared to the central
heating. This might be attributed to the use of one phantom for all central heating measurements and
another phantom for all eccentric heating measurements. A positioning error of the thermistor probes
could have led to this correlation difference. Additionally, the analysis also illustrates a potential setup
error at Institution 5 for centric heating target, in which some of the thermistor probes could have been
slightly miss-positioned with respect to the MRT axial central plane. This effect was not observed for
the measurements for eccentric target.
The Bland-Altman analysis (Figures 4 and 7) showed an overall mean difference between thermistor
probes measurements and MRT of 0.46 ± 0.20 (0.15–0.65) ◦C and 0.13 ± 0.08 (0.03–0.25) ◦C for centric
and eccentric heating targets, respectively. The RMSE was found to be 0.52 ± 0.31 (0–0.77) ◦C for centric
target and 0.30 ± 0.20 (0–0.48) ◦C for eccentric target. As described above, the larger overall mean
difference between thermistor probes and MRT for centric target in comparison to eccentric target can be
attributed to the use of two different phantoms. Even that the phantoms were constructed in an identical
way, the independent alignment of the probes under CT-guidance can lead to sub-centimetre errors in
the identification of the probe positions. Nevertheless, the differences between thermistor probes and
MRT found, are in agreement with previous publications in which a temperature difference of 1 ◦C
was considered an acceptable clinical limit for the application of hyperthermia [40]. The difference
that we found in our study between both measuring methods is also within the agreement with more
recent works evaluating MRT with invasive temperature probes for deep hyperthermia [11,26–28,37]
and also for local hyperthermia using a head and neck applicator [22,25]. Additionally, in previous
publications, the evaluation was performed in only one hybrid device at one institution, while our
study evaluates the performance of five hybrid devices.
The performed measurements show comparable results between the systems of the five evaluated
institutions. The obtained differences between measured thermistor probes and MRT are within the
previously reported values, below 1 ◦C, and for all the evaluated institutions. The differences obtained
between centric and eccentric heating targets indicate that a more accurate thermistor probe positioning
procedure is needed. Additionally, multiple measurements for each phantom setup and institution
would be required to evaluate the reproducibility of the results. Furthermore, it is important to mention
that three different MR-system types from various vendors (Siemens, Philips, GE) are installed within
the five institutions. The three types of MR-systems feature differences in terms of magnet quality,
technical system performances and sequence parameters of the thermometry protocol (Table 1), which
together may cause a slight variation in the MRT accuracy among the five institutions. This study
indicates that the Universal Applicator performs equally as the other systems using a Sigma Eye
applicator with this setup and a limited number of experiments. The results of this study will help to
develop QA procedures and deliver more uniform treatment quality among institutions in multi-centre
trials. Together this can reflect in improved integration of hyperthermia into the patient treatment
process and thus contribute to achieving higher acceptance in the radiotherapy community.
5. Conclusions
This paper reports the results of the first international multi-institution QA evaluation of
hyperthermia systems in terms of MRT accuracy. This evaluation has been performed identically in all
five institutions equipped with MR-guided hyperthermia systems for the treatment of deep-seated
tumours. An anthropomorphic phantom with human representative dimensions has been developed,
and it has shown to be a valuable tool for QA measurements of the systems that can better reflect the
clinical situation. Good agreement between thermistor probe measurements and MRT was found
within and between institutions for both central and eccentrically located targets. An excellent linear
correlation between thermistor probes measurements and MRT was obtained. This study demonstrates
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the feasibility of inter-institutional QA-related to MR-thermometry and provides a basis to define
standards for the delivery of treatments in MR-guided multi-institutional studies and to elucidate
thermal dose-effect relations.
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